About the OSUCCC – James
At The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), our vision is to create a cancer-free world, one person, one discovery at a time. This underlies everything we do in working to eradicate cancer through research that translates to innovative and highly targeted patient care.
The OSUCCC – James is the only cancer program in the United States that features a National Cancer Institute (NCI)–designated comprehensive cancer center aligned with a nationally ranked academic medical center and a freestanding cancer hospital on the campus of one of the nation’s largest public universities.
Cancer is no longer defined solely by stage and location, but rather by its biologic and genetic makeup. There is no routine cancer — it is different in each person. Working together and utilizing state-of-the-art facilities and technology, clinicians and researchers at Ohio State are speeding the development and delivery of treatments that target the molecules and markers fueling each person’s unique cancer.
At the Forefront of Research
The OSUCCC – James is one of only 46 NCI-designated comprehensive cancer centers in the nation, a designation that we have maintained through competitive renewal since 1976. After the site review for our most recent renewal, we earned the NCI’s highest ranking, “exceptional,” and received a five-year, $23 million NCI support grant. The NCI survey team stated that the OSUCCC – James “should serve as the model for other matrix university-based centers.”
At Ohio State, more than 300 cancer researchers and their teams from 12 of our 14 colleges work collaboratively, across multiple disciplines, to improve the effectiveness of cancer prevention, diagnosis and treatment.
Excellence in Cancer Care
In 1990, Ohio State opened the James Cancer Hospital and Solove Research Institute, the Midwest’s first freestanding cancer hospital, as the patient-care component of The Ohio State University Comprehensive Cancer Center. Ranked by U.S.News & World Report as one of the top hospitals in the nation for cancer care, the James Cancer Hospital and Solove Research Institute is one of only 11 DRG-exempt (diagnosis-related-group-exempt) or PPS-exempt (prospective-payment-system-exempt) institutions in the United States.
At Ohio State, we’ve helped pioneer the transdisciplinary, multimodality approach to cancer treatment and patient care. As a founding member of the National Comprehensive Cancer Network (NCCN), we help establish national guidelines and standards of cancer care.
The OSUCCC – James has more than 200 oncologists, each of whom specializes in just one type of cancer. That expert subspecialization leads to more productive integration with cancer research and, ultimately, to better outcomes. We manage hundreds of active or pending cancer clinical trials, many of which are initiated by OSUCCC – James investigators. Our genetic- and molecular-based research helps us understand each patient’s unique cancer and develop and deliver the targeted therapy that leads to better outcomes, fewer side effects and more hope.
Our disease-site groups combine the expertise of multiple disciplines and modalities including surgical oncologists, medical oncologists, pathologists, radiologists, radiation oncologists, nurses and researchers to provide patients with the latest in cancer detection, diagnosis, treatment and prevention. Patients are cared for by a team of experts who tailor a targeted treatment plan for each individual.
A model of excellence in patient care, the OSUCCC – James has achieved Magnet® designation as part of the American Nurses Credentialing Center (ANCC) Magnet Recognition Program®. This voluntary hospital recognition program is considered the highest honor an organization can receive for quality patient care and professional nursing practice. The OSUCCC – James is fully accredited by The Joint Commission, the American College of Surgeons Commission on Cancer and the Foundation for the Accreditation of Cellular Therapy.